Intercept Pharmaceuticals, Inc.

Informe acción NasdaqGS:ICPT

Capitalización de mercado: US$794.7m

Salud financiera de hoja de balance de Intercept Pharmaceuticals

Salud financiera controles de criterios 5/6

Intercept Pharmaceuticals tiene un patrimonio de los accionistas total de $71.8M y una deuda total de $223.9M, lo que sitúa su ratio deuda-patrimonio en 311.6%. Sus activos y pasivos totales son $393.2M y $321.3M respectivamente.

Información clave

311.6%

Ratio deuda-patrimonio

US$223.86m

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$322.71m
PatrimonioUS$71.85m
Total pasivoUS$321.32m
Activos totalesUS$393.16m

Actualizaciones recientes sobre salud financiera

Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?

Apr 11
Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?

Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?

Dec 20
Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?

Recent updates

Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive

Jun 08
Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive

Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?

Apr 11
Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?

Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?

Dec 20
Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?

Intercept touts Ocaliva benefit in transplant-free survival in liver disease type

Sep 20

Intercept cuts debt further with deal to exchange convertible notes

Sep 02

Intercept reduces debt with repurchases of $327.9M convertible notes

Aug 19

Intercept Pharmaceuticals: Too Risky To Buy At This Stage

Aug 13

Intercept Pharma Q2 2022 Earnings Preview

Aug 02

Intercept to resubmit for FDA approval of NASH candidate after new analysis

Jul 07

Intercept: Increase Of Ocaliva Sales And A Few Catalysts

May 23

Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

May 10
Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

Intercept: Opportunity To Buy On Potential NDA Resubmission Of Ocaliva For NASH

Mar 05

Intercept names Andrew Saik as chief financial officer

Jun 07

Intercept Pharmaceuticals slides as FDA restricts Ocaliva use

May 26

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($383.4M) de ICPT superan a sus pasivos a corto plazo ($90.8M).

Pasivo a largo plazo: Los activos a corto plazo de ICPT ($383.4M) superan a sus pasivos a largo plazo ($230.5M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: ICPT tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de ICPT ha pasado de 383.3% a 311.6% en los últimos 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ICPT tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: Datos insuficientes para determinar si ICPT tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.


Descubre empresas con salud financiera